Vaniqa Topical Cream 13.9pct Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Vaniqa: Topical cream (13.9%)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
Vaniqa 13.9% Top Cr
Drug Image file default-drug-image.png
Vaniqa 13.9% Top Cr

What is this Medicine?

EFLORNITHINE (ee FLOR ni theen) is used on the skin to reduce unwanted facial hair in women.

CVS Pharmacy Patient Statistics for Vaniqa: Topical cream(13.9%)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information
Select a Medication

Vaniqa 13.9% Topical Cream

NDC: 674020040
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Hirsutism

Storage Information
Do not freeze
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Vaniqa 13.9% Topical Cream

Reported Side Effects for Vaniqa 13.9% Topical Cream

Allergic Skin Reaction Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Inflammation Of The Lip Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Balance Problems Incidence:
0.3%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
0.5%*
Severity: MILD
Onset: EARLY
Inflamed Hair Follicles Incidence:
0.5-1.0%*
Severity: MILD
Onset: DELAYED
Decreased Appetite Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Skin Irritation Incidence:
1.0-1.8%*
Severity: MILD
Onset: EARLY
Skin Redness Incidence:
1.3-2.5%*
Severity: MODERATE
Onset: EARLY
Hair Loss Incidence:
1.3-1.5%*
Severity: MILD
Onset: DELAYED
Lightheadedness Incidence:
1.5%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
1.5-2.8%*
Severity: MILD
Onset: EARLY
Dry Skin Incidence:
1.8-3.3%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
2.5%*
Severity: MILD
Onset: EARLY
Itching Incidence:
3.1-3.8%*
Severity: MILD
Onset: RAPID
Headache Incidence:
3.8%*
Severity: MILD
Onset: EARLY
Acne Incidence:
10.0-22.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Compatible - This drug is generally safe to take by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Vaniqa

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5